Aprea Therapeutics, Inc. (APRE) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-01

Key Insights

Aprea Therapeutics has closed a $30 million private placement, providing additional capital to fund its ongoing operations and development programs.
The filing does not indicate any major changes in the company's leadership, material agreements, or financial performance, suggesting a routine business update.
Without additional context about the company's recent performance or pipeline, it is difficult to assess the long-term significance of this capital raise for Aprea Therapeutics' future prospects.

Want the newest filings?

This analysis covers the filing from 2026-04-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-30

Aprea Therapeutics raised approximately $30 million through a private placement of pre-funded warrants and common stock warrants, which provides additional funding to support the company's ongoing operations and drug development efforts.
The company granted the investors registration rights, requiring Aprea to file a registration statement to enable the resale of the shares underlying the warrants, improving the liquidity of these securities.
The warrants have customary terms, including limitations on ownership concentration, cashless exercise provisions, and lack of price-based anti-dilution protections, suggesting balanced terms for both the company and investors.

Filed: 2026-03-16

Aprea Therapeutics reported its Q4 2025 and full-year 2025 financial results, providing an update on its operations during the period.
The company updated its corporate presentation slide deck, which may provide additional insights into its business strategy and development pipeline.
As an 8-K filing, this report discloses material information that may be of interest to investors, such as financial performance and corporate developments.

Filed: 2026-01-29

Aprea Therapeutics has raised approximately $5.6 million in a private placement of common stock and warrants, providing additional capital to fund the company's operations.
The company has granted the investors registration rights, requiring Aprea to file a registration statement within 60 days to allow for the resale of the shares issued in the private placement.
The warrants issued in the transaction have a 2-year exercise period and contain favorable terms, including the ability to exercise on a cashless basis and no price reset provisions.

Filed: 2026-01-23

Aprea Therapeutics has received a notice from Nasdaq that its stock price has fallen below the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The company has been given a 180-day compliance period to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
If the company fails to regain compliance within the initial 180-day period, it may be eligible for a second 180-day compliance period, but if it is unable to comply by the end of the extended period, its stock may be subject to delisting.

Filed: 2026-01-09

Aprea Therapeutics has updated its corporate presentation slide deck, which may provide investors with new information about the company's strategic direction and key developments.
The filing does not indicate any major events or changes, suggesting this is a routine update to the company's investor materials.
Investors should review the updated presentation for any significant updates on the company's pipeline, financial performance, or other material information.

Other reports for Aprea Therapeutics, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.